Forty one patients underwent craniospinal irradiation and 27 patients received adjuvant chemotherapy.

Multivariate analysis retained previous adjuvant chemotherapy as a negative survival prognostic factor.

The median duration of adjuvant chemotherapy was 18 weeks in both groups.

Additionally, the benefit of adjuvant chemotherapy post-liver resection remained in sensitivity analysis.

Methodology: 30 patients received adjuvant chemotherapy following surgical resection for pancreatic cancer.

The patient received adjuvant chemotherapy according to Ewing's sarcoma chemotherapy protocol.

Neither adjuvant chemotherapy nor radiotherapy had been given after the operation.

Further evidence is needed to characterize the role of adjuvant chemotherapy.

Patients were randomized to receive either adjuvant chemotherapy or observation after surgical resection.

Seven patients were treated with adjuvant chemotherapy following surgery with a cisplatin-containing combination.

Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy.

One month after surgery the patient began adjuvant chemotherapy with gemcitabine.

Surgical resection was the treatment of choice, occasionally with adjuvant chemotherapy.

Based on recent evidence, platinum-based adjuvant chemotherapy after complete resection should be considered.

Additionally, several metanalysis failed to demonstrate a significant survival advantage with adjuvant chemotherapy.

Several clinical trials of adjuvant chemotherapy are now underway in Japan.